• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HES6 增强肺泡横纹肌肉瘤细胞的运动能力。

HES6 enhances the motility of alveolar rhabdomyosarcoma cells.

机构信息

MRC Cancer Cell Unit, Hutchison-MRC Research centre, Addenbrooke's Hospital Cambridge, UK.

出版信息

Exp Cell Res. 2013 Jan 1;319(1):103-12. doi: 10.1016/j.yexcr.2012.08.010. Epub 2012 Sep 14.

DOI:10.1016/j.yexcr.2012.08.010
PMID:22982728
Abstract

HES6, a member of the hairy-enhancer-of-split family of transcription factors, plays multiple roles in myogenesis. It is a direct target of the myogenic transcription factor MyoD and has been shown to regulate the formation of the myotome in development, myoblast cell cycle exit and the organization of the actin cytoskeleton during terminal differentiation. Here we investigate the expression and function of HES6 in rhabdomyosarcoma, a soft tissue tumor which expresses myogenic genes but fails to differentiate into muscle. We show that HES6 is expressed at high levels in the subset of alveolar rhabdomyosarcomas expressing PAX/FOXO1 fusion genes (ARMSp). Knockdown of HES6 mRNA in the ARMSp cell line RH30 reduces proliferation and cell motility. This phenotype is rescued by expression of mouse Hes6 which is insensitive to HES6 siRNA. Furthermore, expression microarray analysis indicates that the HES6 knockdown is associated with a decrease in the levels of Transgelin, (TAGLN), a regulator of the actin cytoskeleton. Knockdown of TAGLN decreases cell motility, whilst TAGLN overexpression rescues the motility defect resulting from HES6 knockdown. These findings indicate HES6 contributes to the pathogenesis of ARMSp by enhancing both proliferation and cell motility.

摘要

HES6 是 hairy-enhancer-of-split 家族转录因子的成员,在肌发生中发挥多种作用。它是肌源性转录因子 MyoD 的直接靶标,已被证明可调节发育中的体节形成、成肌细胞细胞周期退出以及终末分化过程中肌动蛋白细胞骨架的组织。在这里,我们研究了 HES6 在横纹肌肉瘤中的表达和功能,横纹肌肉瘤是一种表达肌源性基因但不能分化为肌肉的软组织肿瘤。我们发现 HES6 在表达 PAX/FOXO1 融合基因的肺泡横纹肌肉瘤亚组中高表达 (ARMSp)。在 ARMSp 细胞系 RH30 中敲低 HES6 mRNA 会降低增殖和细胞迁移能力。这种表型可以通过表达对 HES6 siRNA 不敏感的小鼠 Hes6 来挽救。此外,表达微阵列分析表明,HES6 敲低与肌动蛋白细胞骨架调节剂 Transgelin(TAGLN)水平降低有关。TAGLN 的敲低会降低细胞迁移能力,而 TAGLN 的过表达则可以挽救由于 HES6 敲低导致的迁移缺陷。这些发现表明 HES6 通过增强增殖和细胞迁移来促进 ARMSp 的发病机制。

相似文献

1
HES6 enhances the motility of alveolar rhabdomyosarcoma cells.HES6 增强肺泡横纹肌肉瘤细胞的运动能力。
Exp Cell Res. 2013 Jan 1;319(1):103-12. doi: 10.1016/j.yexcr.2012.08.010. Epub 2012 Sep 14.
2
Hes6 is required for actin cytoskeletal organization in differentiating C2C12 myoblasts.Hes6 对于分化的 C2C12 成肌细胞中的肌动蛋白细胞骨架组织是必需的。
Exp Cell Res. 2011 Jul 1;317(11):1590-602. doi: 10.1016/j.yexcr.2011.03.023. Epub 2011 Apr 9.
3
HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation.HES6 基因在神经胶质瘤中选择性过表达,是神经胶质瘤增殖的重要转录调节因子。
Oncogene. 2012 Mar 8;31(10):1299-310. doi: 10.1038/onc.2011.316. Epub 2011 Jul 25.
4
Hes6 regulates myogenic differentiation.Hes6调节肌源性分化。
Development. 2002 May;129(9):2195-207. doi: 10.1242/dev.129.9.2195.
5
HES6 acts as a transcriptional repressor in myoblasts and can induce the myogenic differentiation program.HES6在成肌细胞中作为转录抑制因子发挥作用,并可诱导肌源性分化程序。
J Cell Biol. 2001 Sep 17;154(6):1161-71. doi: 10.1083/jcb.200104058. Epub 2001 Sep 10.
6
Hes6 inhibits astrocyte differentiation and promotes neurogenesis through different mechanisms.Hes6通过不同机制抑制星形胶质细胞分化并促进神经发生。
J Neurosci. 2006 Oct 25;26(43):11061-71. doi: 10.1523/JNEUROSCI.1358-06.2006.
7
Overexpression of HES6 has prognostic value and promotes metastasis via the Wnt/β-catenin signaling pathway in colorectal cancer.HES6 过表达具有预后价值,并通过 Wnt/β-连环蛋白信号通路促进结直肠癌的转移。
Oncol Rep. 2018 Sep;40(3):1261-1274. doi: 10.3892/or.2018.6539. Epub 2018 Jul 2.
8
Inhibition of cortical astrocyte differentiation by Hes6 requires amino- and carboxy-terminal motifs important for dimerization and phosphorylation.Hes6对皮质星形胶质细胞分化的抑制作用需要对二聚化和磷酸化至关重要的氨基末端和羧基末端基序。
J Neurochem. 2007 Dec;103(5):2022-34. doi: 10.1111/j.1471-4159.2007.04902.x. Epub 2007 Sep 14.
9
HES6-1 and HES6-2 function through different mechanisms during neuronal differentiation.HES6-1 和 HES6-2 在神经元分化过程中通过不同的机制发挥作用。
PLoS One. 2010 Dec 2;5(12):e15459. doi: 10.1371/journal.pone.0015459.
10
Expression of hes6, a new member of the Hairy/Enhancer-of-split family, in mouse development.
Mech Dev. 2000 Jul;95(1-2):275-8. doi: 10.1016/s0925-4773(00)00348-8.

引用本文的文献

1
Pan-cancer analysis reveals dual roles of HES6 in cancer immunity and prognosis.泛癌分析揭示了HES6在癌症免疫和预后中的双重作用。
Discov Oncol. 2025 Jun 15;16(1):1110. doi: 10.1007/s12672-025-02852-1.
2
Zebrafish her3 knockout impacts developmental and cancer-related gene signatures.斑马鱼 her3 基因敲除影响发育和癌症相关基因特征。
Dev Biol. 2023 Apr;496:1-14. doi: 10.1016/j.ydbio.2023.01.003. Epub 2023 Jan 23.
3
Recent advances in understanding the role of HES6 in cancers.近年来对 HES6 在癌症中的作用的认识进展。
Theranostics. 2022 May 20;12(9):4374-4385. doi: 10.7150/thno.72966. eCollection 2022.
4
Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease.单细胞 RNA 测序揭示原发性眼葡萄膜黑素瘤中的肿瘤内异质性,并鉴定出 HES6 是转移性疾病的驱动基因。
Cell Death Differ. 2021 Jun;28(6):1990-2000. doi: 10.1038/s41418-020-00730-7. Epub 2021 Jan 18.
5
Rhabdomyosarcoma and Extraosseous Ewing Sarcoma.横纹肌肉瘤和骨外尤文肉瘤。
Children (Basel). 2018 Dec 10;5(12):165. doi: 10.3390/children5120165.
6
Overexpression of HES6 has prognostic value and promotes metastasis via the Wnt/β-catenin signaling pathway in colorectal cancer.HES6 过表达具有预后价值,并通过 Wnt/β-连环蛋白信号通路促进结直肠癌的转移。
Oncol Rep. 2018 Sep;40(3):1261-1274. doi: 10.3892/or.2018.6539. Epub 2018 Jul 2.
7
LncSHRG promotes hepatocellular carcinoma progression by activating .长链非编码RNA SHRG通过激活……促进肝细胞癌进展。 (原文此处不完整)
Oncotarget. 2017 Aug 3;8(41):70630-70641. doi: 10.18632/oncotarget.19906. eCollection 2017 Sep 19.